文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

全脑放疗未改善EGFR突变非小细胞肺癌软脑膜转移患者的总生存

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
PubMed 文献 · Radiat Oncol · 2019-09-14

该回顾性研究纳入51例EGFR突变非小细胞肺癌软脑膜转移患者,其中26例接受全脑放疗(WBRT)、25例未接受。两组颅内客观缓解率与疾病控制率无显著差异,WBRT组中位OSLM为13.6个月、非WBRT组为5.7个月(HR=0.454,p=0.022),但多因素分析显示WBRT并非OSLM的独立预测因素(HR=0.49,95%CI:0.24-1.01;p=0.54)。结论认为WBRT未在统计学上改善颅内治疗反应和生存。

要点

  • WBRT组与非WBRT组颅内ORR(15.4% vs 16%,p=0.952)和DCR(34.7% vs 28%,p=0.611)无显著差异。
  • 全队列中位iPFSLM为3.3个月(95%CI:2.77-3.83),中位OSLM为12.6个月(95%CI:9.66-15.54)。
  • 多因素分析中KPS≥80(HR=0.428,95%CI:0.19-0.94;p=0.034)和EGFR-TKI治疗(HR=0.258,95%CI:0.11-0.58;p=0.001)为OSLM独立预测因素,WBRT不是。

核心结论

  • 对于EGFR突变非小细胞肺癌软脑膜转移患者,WBRT未在统计学上改善颅内治疗反应和生存。

研究设计与样本

  • 回顾性研究纳入2014年7月至2018年3月在山东省肿瘤医院就诊的51例EGFR突变非小细胞肺癌软脑膜转移患者,分为WBRT组26例和非WBRT组25例,软脑膜转移经脑脊液细胞学阳性和/或软脑膜增强MRI诊断,采用Kaplan-Meier法估计生存。

主要发现

  • 两组颅内ORR分别为15.4%和16%(p=0.952),DCR分别为34.7%和28%(p=0.611),均无显著差异。
  • 全队列中位iPFSLM为3.3个月(95%CI:2.77-3.83),中位OSLM为12.6个月(95%CI:9.66-15.54)。
  • WBRT组与非WBRT组中位iPFSLM分别为3.9个月和2.8个月(HR=0.506,p=0.052),中位OSLM分别为13.6个月和5.7个月(HR=0.454,p=0.022)。
  • 多因素分析显示KPS≥80(HR=0.428,95%CI:0.19-0.94;p=0.034)和EGFR-TKI治疗(HR=0.258,95%CI:0.11-0.58;p=0.001)是OSLM的独立预测因素,WBRT不是(HR=0.49,95%CI:0.24-1.01;p=0.54)。
  • WBRT或其他治疗相关毒性罕见。

临床怎么用

  • 在EGFR突变非小细胞肺癌软脑膜转移患者中,WBRT不应作为改善颅内反应或生存的常规推荐,应结合KPS和EGFR-TKI治疗等预后因素综合决策。

局限性

  • 本研究为单中心回顾性研究,样本量较小(共51例),结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor receptor (EGFR) mutations. The role of whole brain radiation therapy (WBRT) in the treatment of EGFR-mutant NSCLC patients with LM is not conclusive. Therefore, we conducted a retrospective study to evaluate the therapeutic effect of WBRT in this setting. METHODS: EGFR-mutant NSCLC patients with LM, who had previously received treatment at the Shandong Cancer Hospital and Institute from July 2014 to March 2018 were reviewed retrospectively. LM was diagnosed by positive CSF cytology and/or leptomeningeal-enhanced magnetic resonance imaging (MRI). Survival was estimated using the Kaplan-Meier method. RESULTS: In total, 51 EGFR-mutated NSCLC patients with LM were eligible for analysis, subdivided into 26 in the WBRT group and 25 in the non-WBRT group. No significant differences were observed in intracranial ORR (15.4% vs. 16%, p = 0.952) and DCR (34.7% vs. 28%, p = 0.611) between the two groups. The median iPFSLM and OSLM for the entire cohort were 3.3 months (95% CI: 2.77-3.83) and 12.6 months (95% CI: 9.66-15.54), respectively. No difference in iPFSLM was observed between the WBRT and non-WBRT groups (median 3.9 vs. 2.8 months; HR = 0.506, p = 0.052). The median OSLM was 13.6 months in the WBRT group, compared with 5.7 months in the non-WBRT group (HR = 0.454, p = 0.022). Multivariate analyses of OSLM showed that KPS ≥ 80 at the time of LM diagnosis (HR = 0.428, 95% CI: 0.19-0.94; p = 0.034) and the administration of EGFR-TKIs (HR = 0.258, 95% CI: 0.11-0.58; p = 0.001) were independent predictors of survival, but WBRT (HR = 0.49, 95% CI: 0.24-1.01; p = 0.54) was not. Toxicities associated with WBRT or other treatment were rare. CONCLUSION: For EGFR-mutated NSCLC patients with LM, WBRT did not improve intracranial treatment response and survival statistically.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yan W, Liu Y, Li J, et al. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Radiat Oncol. 2019. PMID: 31521171. doi:10.1186/s13014-019-1376-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。